NATH BIOGENES (INDIA)
Back to Balance Sheet
|
NATH BIOGENES (INDIA) Last 5 Year Current Liabilities History
[Consolidated]
| Mar2025 | Mar2024 | Mar2023 | Mar2022 | Mar2013 | |
|---|---|---|---|---|---|
| Current Liabilities | - | - | - | - | - |
What is the latest Current Liabilities ratio of NATH BIOGENES (INDIA) ?
| Year | Current Liabilities |
|---|---|
| Mar2025 | - |
| Mar2024 | - |
| Mar2023 | - |
| Mar2022 | - |
| Mar2013 | - |
How is Current Liabilities of NATH BIOGENES (INDIA) Trending?
| Years | Current Liabilities | % Change | |
|---|---|---|---|
| Mar2025 | - | 0 | |
| Mar2024 | - | 0 | |
| Mar2023 | - | 0 | |
| Mar2022 | - | 0 | |
| Mar2013 | - | - | |
Compare Current Liabilities of peers of NATH BIOGENES (INDIA)
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| NATH BIOGENES (INDIA) | ₹324.0 Cr | -1.9% | 21% | 12.6% | Stock Analytics | |
| BOMBAY BURMAH TRADING CORPORATION | ₹10,663.2 Cr | 2.1% | 1% | -18.7% | Stock Analytics | |
| KAVERI SEED COMPANY | ₹4,853.8 Cr | 2% | 18.4% | -40.5% | Stock Analytics | |
| VENKYS (INDIA) | ₹2,258.9 Cr | 7% | 28.3% | -6.6% | Stock Analytics | |
| BOMBAY SUPER HYBRID SEEDS | ₹1,059.0 Cr | -1.7% | 28.1% | -17% | Stock Analytics | |
| INDO US BIOTECH | ₹214.6 Cr | -0% | 4.2% | -36.7% | Stock Analytics | |
NATH BIOGENES (INDIA) Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| NATH BIOGENES (INDIA) | -1.9% |
21% |
12.6% |
| SENSEX | 3.2% |
5% |
5.5% |
You may also like the below Video Courses